Healthcare
Trulieve Cannabis Corp.(TCNNF)
Live Price
Offline$10.35
-10.39% today
1Y Change
+201.53%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.63B
- Revenue Growth
- +1.3%
- EPS Growth
- +24.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trulieve Cannabis Corp. (TCNNF) is a Healthcare stock with a market cap of $1.63B and listed on OTC. The stock last traded around $10.35 and up 201.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +1.3%, EPS growth of +24.4%, a dividend yield of 0.0%. What stands out right now is revenue +1.3%, EPS +24.4%, free cash flow +55.1% with operating margin 12.6% and ROIC -7.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Stock Foundry combines TCNNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.3% vs +7.6% peer median
Operating Margin
Below sector median
+12.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.3% and EPS at +24.4%, with operating margin around 12.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +16.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -5.5% | -14.2% | +26.1% |
2026 Feb 26, 2026 | -196.2% | -1.7% | -5.7% | -10.8% |
2025 Aug 6, 2025 | -7.6% | +2.8% | +70.5% | +37.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCNNF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TCNNF Max Drawdown
-54.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TCNNF and SPY.
Company Overview
Trulieve Cannabis Corp.
Other OTC
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edible, vaporizer cartridge, concentrate, topical, capsule, tincture, dissolvable powder, and nasal spray products under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands. As of March 16, 2022, it operated 162 dispensaries, which included 113 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, two dispensaries in Massachusetts, two dispensaries in West Virginia, and one dispensary in Connecticut. Trulieve Cannabis Corp. also operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.
- Leadership
- Kimberly Rivers
- IPO Date
- Sep 27, 2018
- Employees
- 6.0k
- Street Address
- 6749 Ben Bostic Road
- Mailing
- Quincy, FL, 32351
- Region
- Quincy, FL, US
- Reporting Currency
- USD
- Investor Line
- 850 480 7955
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 6.4
- Price/Sales
- 1.4
- Price/Book
- 1.6
Growth
- Revenue
- +1.3%
- EPS
- +24.4%
- Free Cash Flow
- +55.1%
Profitability
- Gross Margin
- 57.7%
- Operating Margin
- 12.6%
- Net Margin
- -9.9%
- ROE
- -9.7%
- ROIC
- -7.2%
Balance Sheet
- Debt/Equity
- 0.58
- Current Ratio
- 4.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.